X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/08/07/2925910/0/en/Inhibikase-Therapeutics-to-Report-Second-Quarter-2024-Financial-Results-on-August-14-2024.html
https://www.globenewswire.com/news-release/2024/06/17/2899626/0/en/Inhibikase-Therapeutics-Completes-Enrollment-of-the-Phase-2-201-Trial-Evaluating-Risvodetinib-in-Untreated-Parkinson-s-Disease.html
https://www.globenewswire.com/news-release/2024/06/05/2893833/0/en/Inhibikase-Therapeutics-Announces-Expansion-to-its-Therapeutic-Pipeline-and-Updates-its-Research-and-Development-Programs.html
https://www.globenewswire.com/news-release/2024/05/20/2884830/0/en/Inhibikase-Therapeutics-Announces-Pricing-of-Registered-Direct-Offering-and-Warrant-Inducement-Priced-At-The-Market-for-Aggregate-Gross-Proceeds-of-4-0-Million.html
https://www.globenewswire.com/news-release/2024/05/16/2883031/0/en/Inhibikase-Therapeutics-Reports-First-Quarter-Financial-Results-and-Highlights-Recent-Period-Activity.html
https://www.globenewswire.com/news-release/2024/05/15/2882451/0/en/Inhibikase-Therapeutics-Announces-Request-for-Withdrawal-of-S-1-Registration-Statement.html
https://www.globenewswire.com/news-release/2024/05/09/2878689/0/en/Inhibikase-Therapeutics-Announces-Final-Pre-IND-Meeting-Outcomes-for-IkT-001Pro-as-a-Treatment-for-Pulmonary-Arterial-Hypertension.html
https://www.globenewswire.com/news-release/2024/04/18/2865848/0/en/Inhibikase-Therapeutics-Issues-Letter-to-Shareholders-and-Provides-Update-on-Development-Programs.html
https://www.globenewswire.com/news-release/2024/04/03/2856913/0/en/Inhibikase-Therapeutics-Announces-Pre-IND-Meeting-with-the-FDA-for-IkT-001Pro-in-Pulmonary-Arterial-Hypertension.html
https://www.globenewswire.com/news-release/2024/03/27/2853623/0/en/Inhibikase-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Highlights-Recent-Activity.html
Market Place
Share 
